CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. [5] It is usually considered …

Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML. Other targeted agents have not achieved …

2024年12月24日 · CD33 (CD33 Molecule) is a Protein Coding gene. Diseases associated with CD33 include Cardiovascular System Disease and Myeloid Leukemia. Among its related …

CD33 is a sialoadhesin molecule that belongs to the immunoglobulin supergene family. It is primarily expressed by myeloid stem cells, myeloblasts, monoblasts, …

CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML) blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as target for …

CD33 is a transmembrane protein that belongs to the Siglecs (sialic-acid-binding immunoglobulin-like lectins) family. In normal individuals, expression of CD33 is associated with myeloid …

CD33 is a transmembrane receptor of the innate immune system that is expressed on the surface of peripheral monocytes and microglial cells in the brain. CD33 was first implicated in …

2014年6月13日 · Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 …

CD33 (siglec-3), a well-known target in leukemia therapy, is an inhibitory sialoadhesin expressed in human leukocytes of the myeloid lineage and some lymphoid subsets, including NK cells. It …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …